BOSTON, Sept. 27, 2019 /PRNewswire-PRWeb/ -- MyBioGate Inc., a company that promotes and facilitates cross-border
Mybiogate PITCH and MATCH events provide a platform to investors and companies, where they get to know each other in advance and can subsequently follow up through presentations, Q&A and one-on-one meetings.
In the opening, Dr. Ding, Director of Investment Analyst from MyBioGate Inc. encouraged western companies to actively explore the China opportunity and emphasized that despite the CFIUS reform, Chinese companies remain to be interested in investing in innovations all around the world, including United States. The in-licensing deals are not perceived to be restricted and thus reached a record high in 2018.
Nine companies took part in the Boston chapter of the PITCH & MATCH event. Each gave an 8-minute presentation about their cutting-edge science, and the business opportunities that brings globally and in Chinese market, in front of a diverse audience consisting of industrial KOLs and investors from well-known institutions.
Majority of the participating companies focused on therapeutics. For example, Virometix, a Swiss biotechnology company, showcased their technology for designing synthetic vaccines to prevent infectious diseases and treat chronic diseases. Another company, Feldan Therapeutics, grabbed attention by virtue of their proprietary peptide-based delivery platform for direct introduction of proteins into target cells.
Medical devices were also a major area of focus in this event. Sensus Healthcare, Inc., a clinical stage company looking for partners to expand into Chinese market, showed impressive results from use of a targeted single dose triple-modulated radiotherapy and Brachytherapy device.
Interestingly, the therapeutics pitched at this event were not just limited to human diseases. Hemomed, a pre-clinical stage biotech, pitched its lead product for developing and marketing a Canine Anemia drug, produced through its patented, platform technology, EAF PEGylation of Hemoglobin.
Finally, participating companies also came in different sizes. RNP Therapeutics, a seed stage biotechnology company attracted as much attention as Sorrento Therapeutics, a clinical stage biotechnology company with a rich and diverse pipeline.
"The Pitch and Match session at China Focus generated a high level of interest from investors and was a way to quickly connect with a relevant and sizeable audience. We are in due diligence with two companies as a result." Cited from Anna Sumeray, CEO of Virometix AG. "I was really glad I had a chance to attend China Focus@BWB at Boston in 2019. It provided great opportunity to meet entrepreneurs, investors and make new friends. It is honored to present my startup company (RNP Therapeutics) in front of investors, who later on might be interested in further discussion. One-on-one meeting is extremely useful to make connection. I hope I can attend next meeting in future." Tom Wang, Acting CFO of RNP Therapeutics responded to us with a passion.
For more information, please visit: https://events.mybiogate.com/biotechweekboston/
Mybiogate's next event with PITCH and MATCH is at China Focus @Europe Hamburg is slated for November 10 at Grand Elysée Hamburg, Hamburg, Germany (https://events.mybiogate.com/europe/).
About China Focus
China Focus is bringing together investors, pharma leaders and innovators from China and around the world for an exclusive partnering event designed to inspire, educate and foster cross-border investment and collaboration in leading biopharma innovations. The forum features premier 1-to-1 networking opportunities prior to and during the forum.
For questions and inquiries: Feier Chen Marketing Manager
7707 Fannin Street Ste. 200 Houston, TX 77054 United States
Phone: (832) 497-2220 Email: email@example.com
Source: MyBioGate Inc.(https://events.mybiogate.com/)
SOURCE MyBioGate Inc.
Subscribe to our Free Newsletters!